| 2016 ESC/EAS guidelines for the management of dyslipidaemias AL Catapano, I Graham, G De Backer, O Wiklund, MJ Chapman, H Drexel, ... Polish Heart Journal (Kardiologia Polska) 74 (11), 1234-1318, 2016 | 9640* | 2016 |
| Circulating endothelial progenitor cells, vascular function, and cardiovascular risk JM Hill, G Zalos, JPJ Halcox, WH Schenke, MA Waclawiw, AA Quyyumi, ... New England Journal of Medicine 348 (7), 593-600, 2003 | 4760 | 2003 |
| Endothelial function and dysfunction: testing and clinical relevance JE Deanfield, JP Halcox, TJ Rabelink Circulation 115 (10), 1285-1295, 2007 | 4309* | 2007 |
| Guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio … Developed with the Special Contribution of the European Association for ... European heart journal 31 (20), 2501-2555, 2010 | 3358 | 2010 |
| Prognostic value of coronary vascular endothelial dysfunction JPJ Halcox, WH Schenke, G Zalos, R Mincemoyer, A Prasad, ... Circulation 106 (6), 653-658, 2002 | 1960 | 2002 |
| Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial … H Brunner, JR Cockcroft, J Deanfield, A Donald, E Ferrannini, J Halcox, ... Journal of hypertension 23 (2), 233-246, 2005 | 980 | 2005 |
| Screening for atrial fibrillation: a report of the AF-SCREEN international collaboration B Freedman, J Camm, H Calkins, JS Healey, M Rosenqvist, J Wang, ... Circulation 135 (19), 1851-1867, 2017 | 634 | 2017 |
| Assessment of remote heart rhythm sampling using the AliveCor heart monitor to screen for atrial fibrillation: the REHEARSE-AF study JPJ Halcox, K Wareham, A Cardew, M Gilmore, JP Barry, C Phillips, ... Circulation 136 (19), 1784-1794, 2017 | 612 | 2017 |
| Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study JR Banegas, E López-García, J Dallongeville, E Guallar, JP Halcox, ... European heart journal 32 (17), 2143-2152, 2011 | 568 | 2011 |
| Secondary prevention through cardiac rehabilitation: physical activity counselling and exercise training: key components of the position paper from the Cardiac Rehabilitation … EACPR Committee for Science Guidelines, U Corrà, MF Piepoli, F Carré, ... European heart journal 31 (16), 1967-1974, 2010 | 524 | 2010 |
| ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of … European Association for Cardiovascular Prevention & Rehabilitation, ... Eur Heart J 32 (14), 1769-818, 2011 | 486 | 2011 |
| Predisposition to atherosclerosis by infections: role of endothelial dysfunction A Prasad, J Zhu, JPJ Halcox, MA Waclawiw, SE Epstein, AA Quyyumi Circulation 106 (2), 184-190, 2002 | 450 | 2002 |
| Endothelial function predicts progression of carotid intima-media thickness JPJ Halcox, AE Donald, E Ellins, DR Witte, MJ Shipley, EJ Brunner, ... Circulation 119 (7), 1005-1012, 2009 | 448 | 2009 |
| Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non … CA Bannister, SE Holden, S Jenkins‐Jones, CL Morgan, JP Halcox, ... Diabetes, Obesity and Metabolism 16 (11), 1165-1173, 2014 | 443 | 2014 |
| The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia JPJ Halcox, KRA Nour, G Zalos, R Mincemoyer, MA Waclawiw, CE Rivera, ... Journal of the American College of Cardiology 40 (7), 1232-1240, 2002 | 360 | 2002 |
| Association between polymorphism in the chemokine receptor CX3CR1 and coronary vascular endothelial dysfunction and atherosclerosis DH McDermott, JPJ Halcox, WH Schenke, MA Waclawiw, MN Merrell, ... Circulation research 89 (5), 401-407, 2001 | 324 | 2001 |
| Antibodies to human heat-shock protein 60 are associated with the presence and severity of coronary artery disease: evidence for an autoimmune component of atherogenesis J Zhu, AA Quyyumi, D Rott, G Csako, H Wu, J Halcox, SE Epstein Circulation 103 (8), 1071-1075, 2001 | 308 | 2001 |
| Beyond the laboratory: clinical implications for statin pleiotropy JPJ Halcox, JE Deanfield Circulation 109 (21_suppl_1), II-42-II-48, 2004 | 306 | 2004 |
| Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY … KK Ray, HM Colhoun, M Szarek, M Baccara-Dinet, DL Bhatt, VA Bittner, ... The lancet Diabetes & endocrinology 7 (8), 618-628, 2019 | 273 | 2019 |
| Methodological approaches to optimize reproducibility and power in clinical studies of flow-mediated dilation AE Donald, JP Halcox, M Charakida, C Storry, SML Wallace, TJ Cole, ... Journal of the American College of Cardiology 51 (20), 1959-1964, 2008 | 267 | 2008 |
